Tesamorelin

Tesamorelin is a synthetic peptide analogue of human Growth Hormone-Releasing Hormone (GHRH). Structurally, it is based on the full 44-amino-acid chain of GHRH and has been modified at its N-terminus to increase its stability and resistance to enzymatic degradation.

Its mechanism of action involves binding to and stimulating GHRH receptors in the anterior pituitary gland. This action mimics the function of endogenous GHRH, triggering the synthesis and pulsatile release of the body's own supply of growth hormone (GH). The subsequent increase in GH and Insulin-like Growth Factor 1 (IGF-1) levels stimulates various metabolic processes, including lipolysis (the breakdown of fat).

Tesamorelin is distinguished by its specific clinical application. Under the brand name Egrifta®, it is an FDA-approved medication indicated for the reduction of excess visceral adipose tissue (VAT) — a metabolically harmful type of fat that accumulates around internal organs — in adult patients with HIV-associated lipodystrophy. It is the only therapy specifically approved for this condition and is not indicated for general weight loss management.